As global data center expansion strains power grids, Fluence Energy's energy storage solutions are emerging as a critical piece of infrastructure. Despite recent operational headwinds, a massive backlog and structural demand trends paint a bullish picture for the company.
While aggressively deploying AI across its vast logistics network, FedEx is taking a measured, pilot-stage approach to warehouse automation and drones, CEO Raj Subramaniam tells The New York Times. The shipping giant, handling $2 trillion in global commerce, prioritizes scalable infrastructure over unproven robotics for its 17 million daily packages.
Shares of Columbia Financial surged nearly 9% Monday, propelled by a robust quarterly earnings report and the announcement of a nearly $600 million deal to acquire Northfield Bancorp, a move set to create a New Jersey banking powerhouse.
Once a high-flying AI discovery platform, AbCellera Biologics is navigating a critical transition to a clinical-stage biotech. With a fortified balance sheet and key Phase 1 readouts on the horizon, some investors see a compelling, albeit risky, turnaround story taking shape.
Amidst a global push for reliable, carbon-free power, Centrus Energy Corp. (LEU) emerges as a critical supplier in the nuclear fuel chain. With its stock trading near backlog value and recent financial developments reducing execution risk, analysts see a clear path for growth, particularly as AI and data center energy demands surge.
Once a high-flying SaaS leader, PagerDuty now trades near historic lows despite its critical role in digital operations. As the company navigates a painful pricing model transition, improving fundamentals and persistent takeover speculation present a compelling bull case for patient investors.
Amid surging power demands from AI and electrification, NANO Nuclear Energy Inc. (NNE) is attracting bullish investor attention. Analysts point to its microreactor technology as a potential solution for decentralized, high-density energy needs, drawing comparisons to infrastructure giant NextEra Energy's growth trajectory.
Shares of OR Royalties (TSX:OR) have retreated nearly 15% over the past week, prompting investors to reassess the valuation of the precious metals royalty company following its multi-year bull run. With the stock still up significantly year-over-year, we examine whether the dip presents a value entry or reflects justified concerns over its premium pricing.
A landmark all-stock merger between Devon Energy and Coterra Energy is set to create the nation's second-largest independent oil and gas producer, promising significant cost savings and enhanced shareholder returns in a consolidating energy market.
Devon Energy and Coterra Energy announce a strategic, all-stock merger to create a dominant multi-basin U.S. shale operator. The combined entity, centered on the prolific Delaware Basin, targets $1 billion in annual synergies and over $5 billion in shareholder returns, promising enhanced scale and capital efficiency.
InSilico Medicine Cayman TopCo's shares have rocketed over 60% in a month, forcing investors to scrutinize whether its AI-driven drug discovery promise can justify the momentum, especially against a backdrop of persistent losses and a negative book value.
After a period of significant volatility, Neogen Corporation (NEOG) is showing signs of a sustainable operational turnaround under new leadership, with its latest quarterly results beating expectations and prompting a rare guidance upgrade.
A deep dive into the mounting challenges facing Unity Software Inc., from eroding developer trust and fierce competition to financial pressures, as a prominent bear thesis gains traction among investors.
Gilead Sciences, the biopharma giant known for its HIV treatments, is strategically pivoting to become a major player in cancer therapy. Through targeted licensing and a focus on precision oncology, the company aims to build a multi-billion dollar revenue stream by the end of the decade, reducing its reliance on mature franchises.
Facing the looming patent expiration of key drugs Revlimid and Eliquis, Bristol-Myers Squibb is making a strategic pivot, acquiring Orbital Therapeutics for $1.5 billion to pioneer in vivo RNA therapies. This high-stakes move aims to redefine the company's growth in oncology and autoimmune diseases.
AbbVie's $2.1 billion acquisition of Capstan Therapeutics signals a strategic pivot towards next-generation immunology treatments. The move aims to secure future revenue streams as the company navigates the post-Humira era, with analysts highlighting the transformative potential of its in vivo CAR-T platform.
The aerospace and engine leasing specialist defied a mid-year slump with a powerful earnings beat, propelling its stock to a stellar annual gain. Now, with the launch of its FTAI Power data center initiative, the company is aiming to capitalize on the AI-driven energy crunch.
Once a high-flying adtech darling, The Trade Desk has seen its stock crater nearly 80% from its peak amid a fierce battle with Amazon's ad juggernaut. With shares now trading at a significant discount to the market, analysts are divided on whether this marks a historic buying opportunity or signals deeper structural challenges.
A recent SEC filing reveals a major purchase of the Vanguard 0-3 Month Treasury Bill ETF, signaling a strategic move for liquidity and yield in a volatile market.
XRP has found a tentative footing above $1.50 after a market slump, but on-chain data reveals the recovery is being driven by speculative, short-term holders, casting doubt on its sustainability and highlighting key resistance levels ahead.
